Order Article Reprints

Baur S, Ruhwedel T, Böke E, Kobus Z, Lishkova G, Wetz C, Amthauer H, Roderburg C, Tacke F, Rogasch JM, et al. Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing ¹⁷⁷Lu-Based Peptide Receptor Radionuclide Therapy. Cancers. 2026; 18(8):1194. https://doi.org/10.3390/cancers18081194

Baur, Simon, Tristan Ruhwedel, Ekin Böke, Zuzanna Kobus, Gergana Lishkova, Christoph Wetz, Holger Amthauer, Christoph Roderburg, Frank Tacke, Julian M. Rogasch, and et al. 2026. "Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing ¹⁷⁷Lu-Based Peptide Receptor Radionuclide Therapy" Cancers 18, no. 8: 1194. https://doi.org/10.3390/cancers18081194

Baur, S., Ruhwedel, T., Böke, E., Kobus, Z., Lishkova, G., Wetz, C., Amthauer, H., Roderburg, C., Tacke, F., Rogasch, J. M., Samek, W., Jann, H., Ma, J., & Eschrich, J. (2026). Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing ¹⁷⁷Lu-Based Peptide Receptor Radionuclide Therapy. Cancers, 18(8), 1194. https://doi.org/10.3390/cancers18081194